Allakos
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Allakos and buy or sell other stocks, ETFs, and their options commission-free!About ALLK
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.
CEOKevin C. Tang
CEOKevin C. Tang
Employees61
Employees61
HeadquartersSan Carlos, California
HeadquartersSan Carlos, California
Founded2012
Founded2012
Employees61
Employees61
ALLK Key Statistics
Market cap29.74M
Market cap29.74M
Price-Earnings ratio-0.41
Price-Earnings ratio-0.41
Dividend yield—
Dividend yield—
Average volume180.22K
Average volume180.22K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$1.56
52 Week high$1.56
52 Week low$0.2157
52 Week low$0.2157
Stock Snapshot
As of today, Allakos(ALLK) shares are valued at $0.33. The company's market cap stands at 29.74M, with a P/E ratio of -0.41.
Allakos(ALLK) stock opened on 2025-12-21 at —. The price climbed to — and dipped to —.
Allakos(ALLK) shares are trading with a volume of 0, against a daily average of 180.22K.
During the past year, Allakos(ALLK) stock moved between $0.22 at its lowest and $1.56 at its peak.
During the past year, Allakos(ALLK) stock moved between $0.22 at its lowest and $1.56 at its peak.
People also own
Based on the portfolios of people who own ALLK. This list is generated using Robinhood data, and it’s not a recommendation.